Lupin announced that the FDA has granted final approval for the company’s tobramycin inhalation solution, a generic version of Novartis’s TOBI 300 mg/5 ml inhalation solution for the treatment of P. aeruginosa lung infections in cystic fibrosis patients.
The company noted that US sales of tobramycin inhalation solution in 2016 totaled $133.6 million.
Read the Lupin press release.
